Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Transvamix
- Development stage
- Phase 3
- Lead developer
- University Medical Center Groningen
- Modality
- Small Molecules
- Administration
- Sublingual
01
Overview
**Transvamix** is a prescription cannabinoid-based sublingual oil containing delta-9-tetrahydrocannabinol 100 mg/mL and cannabidiol 50 mg/mL, corresponding to 10% THC and 5% CBD. It is a fixed-dose small-molecule cannabinoid formulation prepared by Transvaal Pharmacy using standardized Bedrocan and Bedrolite cannabis raw materials. THC is a partial agonist of cannabinoid receptors, principally CB1, and is intended to modulate nociceptive and affective pain processing; CBD is included as a co-active cannabinoid and may attenuate some THC-related adverse effects. Transvamix has been studied by University Medical Center Groningen in placebo-controlled crossover trials for chronic pain associated with epidermolysis bullosa and in a Phase 2a study for untreatable advanced hepatocellular carcinoma. ([journals.plos.org](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0277512))
- Brand names
- Transvamix
- Other names
- THC 10% + CBD 5% oil
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)HTR3A (5-hydroxytryptamine receptor 3A)ADORA1 (Adenosine receptor A1 subtype)CNR1 (Cannabinoid receptor 1)GPR18 (G protein-coupled receptor 18)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on Transvamix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Transvamix.